Ipca Laboratories Ltd.

NSE: IPCALAB | BSE: 524494 | ISIN: INE571A01038 | Industry: Pharmaceuticals
| Mid-range Performer
1734.2000 -62.10 (-3.46%)
NSE Aug 14, 2026 15:31 PM
Volume: 390.6K
 

1734.20
-3.46%
ICICI Direct
Q4FY26 - Formulations drive numbers- Revenues grew 6.3% YoY to 2388.5 crore, mainly driven by formulations. Domestic formulations grew 12% YoY to 853 crore. Under exports formulations - Branded exports grew ~14% to 190 crore, generic exports also grew 39% YoY to 341 crore whereas Institutional exports de-grew 33% YoY to 74.1 crore. The API business was flat at 344.6 crore. The subsidiaries (including Unichem) performance was also below par with ~6% degrowth to 574 crore. EBITDA grew 13% YoY to 483.9 crore while EBITDA margins improved...
Ipca Laboratories Ltd. has an average target of 1793.75 from 4 brokers.
More from Ipca Laboratories Ltd.
Recommended